Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 23 · below the Ichimoku cloud · RSI 25 (oversold) · MACD below its signal
| 13.90 | 52-week high | +53.08% |
| 13.41 | Previous month high | +47.69% |
| 10.68 | Previous week high | +17.62% |
| 10.36 | Previous month low | +14.10% |
| 10.12 | R3 (classic) | +11.45% |
| 9.90 | R2 (classic) | +9.03% |
| 9.68 | Previous day high | +6.61% |
| 9.49 | R1 (classic) | +4.52% |
| 9.27 | Pivot | +2.09% |
| 9.08 | Price now | |
| 9.05 | Previous day low | −0.33% |
| 9.05 | Previous week low | −0.33% |
| 8.86 | S1 (classic) | −2.42% |
| 8.64 | S2 (classic) | −4.85% |
| 8.23 | S3 (classic) | −9.36% |
| 7.36 | 52-week low | −18.96% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $18.3M | 0.03% | 1.66M | +5.1% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a KURA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 28, 2026 | Ford KathleenChief Operating Officer | Sale at price 10.50 - 10.75 per share. | 10.6K | $111.93K |
| Sep 28, 2026 | Powl Brian TOfficer | Sale at price 10.50 - 10.75 per share. | 32.5K | $345.04K |
| Sep 28, 2026 | Leoni Mollie M.D.Officer | Sale at price 10.50 - 10.75 per share. | 41.3K | $440.24K |
| Sep 27, 2026 | Bair Teresa BrophyOfficer | Sale at price 10.50 per share. | 8.4K | $88.62K |
| Sep 27, 2026 | Doyle Thomas JamesOfficer | Sale at price 10.50 per share. | 4.6K | $48.36K |
| Aug 23, 2026 | Wilson Troy EdwardChief Executive Officer | Purchase at price 12.39 per share. | 100K | $1.24M |
| Aug 20, 2026 | Powl Brian TOfficer | Sale at price 11.89 per share. | 4.3K | $51.66K |
| Aug 18, 2026 | Bair Teresa BrophyOfficer | Sale at price 12.63 per share. | 31.5K | $397.68K |
| Aug 16, 2026 | Wilson Troy EdwardChief Executive Officer | Purchase at price 11.12 per share. | 100K | $1.11M |
| Jun 17, 2026 | Leoni Mollie M.D.Officer | Sale at price 9.82 per share. | 84.9K | $834.28K |
| May 20, 2026 | Powl Brian TOfficer | Sale at price 11.00 per share. | 10K | $110.00K |
| May 18, 2026 | Ford KathleenChief Operating Officer | Sale at price 9.08 per share. | 2.3K | $20.48K |
| May 18, 2026 | Powl Brian TOfficer | Sale at price 9.21 per share. | 339 | $3.12K |
| May 17, 2026 | Bair Teresa BrophyOfficer | Sale at price 9.38 per share. | 2.3K | $21.16K |
| Mar 22, 2026 | Wilson Troy EdwardChief Executive Officer | Conversion of Exercise of derivative security at price 6.15 per share. | 6.1K | $37.53K |
| Mar 17, 2026 | Malley Thomas RobertDirector | Conversion of Exercise of derivative security at price 3.12 per share. | 10K | $31.20K |
| Jan 26, 2026 | Ford KathleenChief Operating Officer | Sale at price 8.46 per share. | 1.8K | $15.34K |
| Jan 26, 2026 | Bair Teresa BrophyOfficer | Sale at price 8.46 per share. | 11.2K | $94.83K |
| Jan 26, 2026 | Doyle Thomas JamesOfficer | Sale at price 8.46 per share. | 7.1K | $60.43K |
| Jan 26, 2026 | Powl Brian TOfficer | Sale at price 8.46 per share. | 6.4K | $54.27K |
TimeframesDown on the hourly, daily and monthly, mixed on the weekly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -21.8 | 7.5 | -6.9 | 8.6 | 15.5 | 7.5 | -17.9 | 40.4 | -15.3 | -15.2 | −12.6% | ||
| 2025 | -9.2 | -2.5 | -14.4 | -0.6 | -13.3 | 1.4 | 4.9 | 30.6 | 12.0 | 16.0 | 18.2 | -14.4 | +19.3% |
| 2024 | 40.1 | 4.7 | 1.2 | -8.0 | 5.0 | -0.1 | 1.1 | 1.2 | -7.2 | -14.4 | -34.0 | -21.1 | −39.4% |
| 2023 | 11.4 | -13.7 | 2.6 | -20.4 | 36.8 | -20.6 | -1.3 | -4.9 | -8.2 | -7.3 | 14.4 | 48.7 | +15.9% |
| 2022 | 0.6 | 12.6 | 1.3 | -10.8 | -8.3 | 39.3 | -16.5 | -9.5 | -1.4 | 13.6 | 1.6 | -21.3 | −11.4% |
| 2021 | -8.3 | -6.5 | 1.0 | -4.7 | -17.4 | -6.3 | -9.2 | -2.5 | 1.5 | -12.3 | -15.0 | 0.3 | −57.1% |
| 2020 | -14.6 | 2.8 | -17.6 | 46.2 | 17.5 | -4.6 | 0.9 | 51.4 | 23.1 | 2.0 | 16.2 | -10.0 | +137.5% |
| 2019 | 13.2 | -4.2 | 8.9 | -8.7 | 5.6 | 23.1 | -2.9 | -20.6 | -0.1 | -1.3 | 6.4 | -13.7 | −2.1% |
| 2018 | 28.1 | 15.3 | -17.0 | -19.2 | 9.9 | 9.3 | 11.5 | 1.0 | -14.6 | -37.9 | 16.8 | 10.6 | −8.2% |
| 2017 | 5.9 | 33.6 | 5.4 | 13.1 | -10.6 | 4.5 | -2.7 | -20.4 | 107.6 | -0.3 | 7.7 | -4.7 | +159.3% |
| 2016 | -42.9 | -14.6 | -1.2 | -18.6 | -10.2 | -8.4 | 51.6 | 40.5 | 8.3 | -35.2 | 19.8 | 21.6 | −29.8% |
| 2015 | 14.3 | -51.4 | 8.1 | −40.0% |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Buy / hold / sell counts